Literature DB >> 29143981

High plasma 25-hydroxyvitamin D and high risk of nonmelanoma skin cancer: a Mendelian randomization study of 97 849 individuals.

U C Winsløw1,2, B G Nordestgaard1,2, S Afzal1,2.   

Abstract

BACKGROUND: High plasma 25-hydroxyvitamin D [25(OH)D] concentration has been associated observationally with a high risk of nonmelanoma skin cancer (NMSC), whereas many studies suggest that vitamin D could have a protective effect against cancer. The true association between vitamin D and risk of skin cancer remains unclear.
OBJECTIVES: To test the hypothesis that genetically high plasma 25(OH)D protects against NMSC.
METHODS: We included 103 084 individuals from the Danish general population, of whom 35 298 had plasma 25(OH)D measured and 97 849 were genotyped for four genetic variants near DHCR7 and CYP2R1 associated with 25(OH)D concentrations. We tested the association between plasma 25(OH)D levels and NMSC observationally and between genetically determined 25(OH)D levels and NMSC, using an instrumental variable approach.
RESULTS: Multivariate-adjusted hazard ratios of NMSC were 3·27 [95% confidence interval (CI) 2·22-4·84] for plasma 25(OH)D ≥ 50 nmol L-1 vs. < 25 nmol L-1 . Genetic variants around DHCR7 and CYP2R1 were associated with up to 8·2 nmol L-1 higher 25(OH)D concentrations (F = 314). The odds ratio (OR) for a genetically determined 20 nmol L-1 higher plasma 25(OH)D was 1·11 (95% CI 0·91-1·35) for NMSC, with a corresponding observational multivariable adjusted OR of 1·13 (95% CI 1·10-1·17).
CONCLUSIONS: Genetically determined high 25(OH)D levels did not appear to protect against NMSC, whereas high plasma 25(OH)D concentrations were associated with an observational high risk of NMSC. Thus, the observational association likely reflects confounding by sun exposure rather than causality.
© 2017 British Association of Dermatologists.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29143981     DOI: 10.1111/bjd.16127

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  6 in total

Review 1.  Vitamin D and Multiple Health Outcomes: An Umbrella Review of Observational Studies, Randomized Controlled Trials, and Mendelian Randomization Studies.

Authors:  Di Liu; Xiaoni Meng; Qiuyue Tian; Weijie Cao; Xin Fan; Lijuan Wu; Manshu Song; Qun Meng; Wei Wang; Youxin Wang
Journal:  Adv Nutr       Date:  2022-08-01       Impact factor: 11.567

2.  Relationship Between Level of Serum 25-Hydroxyvitamin D and Risk of Squamous Cell Carcinoma in an Iranian Population.

Authors:  Mahboobeh-Sadat Hosseini; Fereshteh Salarvand; Amir Houshang Ehsani; Pedram Noormohammadpour; Shadi Azizzadeh; Mohaddese Mousavi; Mona Morsali
Journal:  Dermatol Pract Concept       Date:  2019-10-31

3.  A comprehensive re-assessment of the association between vitamin D and cancer susceptibility using Mendelian randomization.

Authors:  Jue-Sheng Ong; Suzanne C Dixon-Suen; Xikun Han; Jiyuan An; Upekha Liyanage; Jean-Cluade Dusingize; Johannes Schumacher; Ines Gockel; Anne Böhmer; Janusz Jankowski; Claire Palles; Tracy O'Mara; Amanda Spurdle; Matthew H Law; Mark M Iles; Paul Pharoah; Andrew Berchuck; Wei Zheng; Aaron P Thrift; Catherine Olsen; Rachel E Neale; Puya Gharahkhani; Penelope M Webb; Stuart MacGregor
Journal:  Nat Commun       Date:  2021-01-11       Impact factor: 14.919

Review 4.  The health effects of vitamin D supplementation: evidence from human studies.

Authors:  Roger Bouillon; Despoina Manousaki; Cliff Rosen; Katerina Trajanoska; Fernando Rivadeneira; J Brent Richards
Journal:  Nat Rev Endocrinol       Date:  2021-11-23       Impact factor: 47.564

5.  Serum 25-hydroxyvitamin D and risk of cancer in a large community population under investigation for cardiovascular disease: a retrospective cohort study.

Authors:  Jaeun Yang; Yuan Dong; Christopher T Naugler; Lawrence de Koning
Journal:  BMJ Open       Date:  2022-01-19       Impact factor: 2.692

6.  Systematic review of Mendelian randomization studies on risk of cancer.

Authors:  Georgios Markozannes; Afroditi Kanellopoulou; Olympia Dimopoulou; Dimitrios Kosmidis; Xiaomeng Zhang; Lijuan Wang; Evropi Theodoratou; Dipender Gill; Stephen Burgess; Konstantinos K Tsilidis
Journal:  BMC Med       Date:  2022-02-02       Impact factor: 11.150

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.